Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05428449 · ClinicalTrials.gov registry record · Phase 1
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
A Phase 1 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 1
- Development phase
- 123
- Enrollment target
NCT05428449: Completed Phase 1 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
NCT05428449 is a Phase 1 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 123 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05428449, a Phase 1 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 123 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne
Primary Outcome
8 subjects in a group do not experience any Grade 3 or higher AEs (assessed by NAIDS 2017 v2.1) within 7 days after the last dose, the dose can be escalated to the next. Dose-escalation will be stopped if any of the following occur: * a SAE occurs in one or more active-treated subjects that is considered probably or definitely related to study drug * ≥50% subjects receiving active treatment experience a severe non-serious adverse event that is considered probably or definitely related to study
Interventions
- DRUG GT20029 Gel
- DRUG GT20029 Gel Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2023-04-06 |
| Phase | Phase 1 |
What the finished NCT05428449 record still lists
NCT05428449 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 2 interventions - of which GT20029 Gel is the first listed.
NCT05428449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05428449 about?
NCT05428449 is a clinical study titled "Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029". A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopeci...
What is the current status of trial NCT05428449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2022-02-10. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT05428449?
The interventions under investigation include: GT20029 Gel (DRUG), GT20029 Gel Placebo (DRUG).
Who is sponsoring clinical trial NCT05428449?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05428449's enrollment target sits among peer trials
123 475th of 2000 higher than 1,526 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI